Hydrogen bond donors in drug design

This presentation focuses on the differences between hydrogen bond donors (HBDs) and hydrogen bond acceptors (HBAs) in the context of drug design. Analysis of alkane/water partition coefficients shows that HBDs are typically less strongly solvated than HBAs, implying that desolvation penalty is not generally a plausible explanation for HBD-specific ADME liabilities.